Cel Sci Corporation (CVM)

[trickledownfacists]

27

CEL-SCI Reports Monthly Patient Enrollment in November for Its Phase 3 Head and Neck Cancer Trial

Source: Business Wire
CEL-SCI Corporation (NYSE MKT: CVM) ("CEL SCI" or the "Company") today announced that in the month of November it has enrolled 27 patients in its ongoing Phase 3 trial of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) in patients with advanced primary head and neck cancer. Total patient enrollment is now 635 as of November 30, 2015 in the world’s largest Phase 3 study in head and neck cancer.

“This fall we have been enrolling patients at an average of rate one per day. We expect this rate will significantly increase in the first quarter of 2016 based on the number of new clinical centers that are now being activated,” stated CEL-SCI CEO Geert Kersten.

The current study goal is to enroll 880 patients through approximately 100 clinical centers in over 20 countries.